Who is sponsoring NCT02984813?

NCT02984813 is sponsored by The New York Eye & Ear Infirmary.

What condition does NCT02984813 study?

NCT02984813 studies Open-angle Glaucoma, Diabetic Retinopathy.

What drugs are being tested in NCT02984813?

Interventions: GlaucoHealth, GlaucoSelect, Placebo.

What is the status of NCT02984813?

NCT02984813 is currently TERMINATED.

Last reviewed 2021-03-17 · How we verify

Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy

NCT02984813 PHASE1 TERMINATED

This study is a multi-armed protocol designed to evaluate the safety and efficacy of two different combinations of nutritional supplements (study drug) (Glauco-Health and Glauco-Select) chosen for their potential to protect retinal ganglion cells against oxidative stress, low-grade inflammation, and mitochondrial dysfunction in patients with open-angle glaucoma and diabetic retinopathy. Oxidative stress and retinal cellular dysfunction will be measured using a Retinal Metabolic Analyzer (RMA) in this randomized, single center, double masked study. Patients with glaucoma will be divided into three treatment arms randomized to receive either Glauco-Health, Glauco-Select, or placebo.

Details

Lead sponsor	The New York Eye & Ear Infirmary
Phase	PHASE1
Status	TERMINATED
Enrolment	21
Start date	Fri Apr 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Sun Jan 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Open-angle Glaucoma
Diabetic Retinopathy

Interventions

GlaucoHealth
GlaucoSelect
Placebo

Countries

United States